2197 Share Price Performance
Recent 2197 News & Updates
No updates
Clover Biopharmaceuticals, Ltd. Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.70
- Gross Margin
- -1,751.59%
- Net Profit Margin
- -2,351.51%
- Debt/Equity Ratio
- -4.5%
Clover Biopharmaceuticals, Ltd. Competitors
About 2197
- Founded
- 2007
- Employees
- 300
- CEO
- WebsiteView website
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China and internationally. The company’s product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza A and B; and SCB-219M, a thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia. It is also developing SCB-2023B for COVID-19 treatment; SCB-1019, a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets; and SCB-1001 for rabies treatment. In addition, the company sells biopharmaceutical drugs. The company was founded in 2007 and is headquartered in Shanghai, the People’s Republic of China.
Chinese Market Performance
- 7 Days: 1.4%
- 3 Months: 12.7%
- 1 Year: 30.0%
- Year to Date: 13.1%
The market is up 1.4% over the last week, with the Information Technology sector leading the way, up 4.0%. In the last year, the market has climbed 30%. Looking forward, earnings are forecast to grow by 23% annually. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
Continue reading